Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

MENLO PARK, Calif., May 23, 2013 /PRNewswire/ -- Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.  

The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults.

"The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay.  "Published preclinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with a variety of painful disorders, including neuropathic pain.  In addition, research carried out by Virobay with selective cathepsin S inhibitors has demonstrated efficacy in preclinical models of both acute and chronic inflammatory pain and neuropathic pain," stated Robert Booth .  "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-036.  To the best of our knowledge, VBY-036 is first-in-class with this therapeutic approach for the treatment of pain."

"Reaching this important milestone brings us one step closer to providing a new treatment for patients suffering with painful conditions.  Virobay is committed to providing novel therapies for unmet medical needs and strives to constantly expand and improve treatment options for patients.  Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year.  VBY-891 is being developed in partnership with LEO Pharma for the
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015  Guggenheim Securities, the investment banking and capital ... of William Tanner as a Managing Director ... will start work at Guggenheim in May 2015 in ... "Bill brings a wealth of biotech experience, ... and highly acclaimed healthcare team," said Matthew Johnson ...
(Date:4/16/2015)... Carolina (PRWEB) April 17, 2015 ... steam system services, released their newly designed, state-of-the-art ... The customer facing website effectively promotes the Spirax ... , All the information that a site visitor ... system services, company capabilities, industries serviced, the latest ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased ... for the 2015 BIO International Convention. Hosted by ... Convention will take place June 15-18 at the Pennsylvania ... BIO contest, industry leaders will be voting for companies ... The community voting period began on April 14, 2015 ...
(Date:4/16/2015)... 16, 2015 The Council for ... prestigious 2015 Borlaug CAST Communication Award goes to ... Tuskegee University in Alabama. Award nominees must demonstrate ... presentations; and/or the use of television, radio, or ... areas. As a specialist in the field of ...
Breaking Biology Technology:Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Spirax Sarco website has a new look 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2
... , DOYLESTOWN, Pa., Sept. 17 Following the ... , the novel self-expanding coronary stent system will be the ... coronary artery disease at TCT 2009 , September ... device, also from Prescient Medical , will be ...
... , BETHESDA, Md., Sept. 17 Micromet, Inc. ... proprietary antibodies for the treatment of cancer, inflammation and autoimmune ... and webcast on September 22, 2009 at 7:00 am U.S. ... clinical trial with Micromet,s anti-EpCAM BiTE antibody MT110, which was ...
... , BOULDER, Colo., Sept. ... been awarded two Phase I Small Business Innovation Research (SBIR) ... and Infectious Diseases (NIAID) of The National Institutes of Health ... preclinical toxicology and pharmacology studies of the company,s proprietary long-acting ...
Cached Biology Technology:TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 2Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009 2Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009 3Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Sometimes the best discoveries come by accident., A ... Louis, headed by Srikanth Singamaneni, PhD, assistant professor ... the mechanism by which tiny single molecules spontaneously ... for a different experiment in the refrigerator., Once ...
... at Ume University in Sweden conclude that public opposition to ... sometimes argued in dam removal science. It is instead a ... the functions it provides. The findings are now published in ... is an increasingly common practice as old splash dams and ...
... the costs and benefits of plastic vegetable greenhouses ... inside plastic greenhouses, particularly for small-holders, have driven ... farmlands worldwide but particularly in China, where ... US $60 million in produce (2008 figures). The ...
Cached Biology News:Watching molecules grow into microtubes 2Controversial dam removals founded on value conflicts 2February highlights from Ecological Society of America publications 2February highlights from Ecological Society of America publications 3February highlights from Ecological Society of America publications 4
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
NORMAL DONOR DONKEY SERUM...
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
Biology Products: